

# LINGUISTIC VALIDATION CERTIFICATE

## Symptom Screen (SymptoMScreen)

This is to certify that **Mapi Language Services** conducted the linguistic validation of the **paper** version of the **SymptoMScreen** (source file name: **SymptoMScreen\_AU1.0\_eng-USori**) into **Spanish for the United States**.

The aim of linguistic validation is to obtain translations that are:

- conceptually equivalent to the original and comparable across languages;
- culturally relevant to the context of the target country;
- easily understood by the people to whom the translated instrument is administered.

This is achieved using a rigorous methodology<sup>1</sup> involving:

- a process which comprises several steps;
- the instrument's developer input on conceptual issues;
- a skilled team recruited by **Mapi Language Services** in the target country and headed by a consultant with knowledge of and experience in the field of Clinical Outcome Assessments. The consultant supervises and coordinates the linguistic validation process in his/her country;
- a centralized review process coordinated by **Mapi Language Services**, including quality control by linguists and discussions about translation decisions with the consultant at each step of the process.
- cross-cultural harmonisation to ensure common understanding of the instrument's concepts by all participants involved in the process and achieve conceptual equivalence across languages.

**The aforementioned translation (filename: **SymptoMScreen\_MA30143\_United States(Spanish)\_Final\_V1.0\_3103017.pdf**, dated **31 March 2017**) underwent the following steps:**

- **Forward Translation step – 2 forward translations by qualified translators and reconciliation**
- **Backtranslation step – 1 backtranslation by a qualified translator**
- **Clinician's Review step by a neurologist**
- **Cognitive Interview step on 5 patients with multiple sclerosis**
- **Proofreading step**

**Note:** In order to encompass the multi-ethnic dimension of US Spanish, the forward translations were produced by one Mexican and one South American translator respectively and reconciled during a meeting held by the consultant with the forward translators and two other translators of Caribbean and Central American origins. The individuals interviewed during cognitive interviews were of the same origins i.e. 2 Mexicans, 1 Caribbean, 1 Central American and 1 South American.

**Mapi Language Services** may not be held liable for any changes made on the translation after completion of project **056819** by **Mapi Language Services** on **31 March 2017**.

### Approved By:

Ana BAYLES  
Managing Director  
Mapi - Language Services



### Mapi SAS

SAS au capital de 434 700 euros  
27 rue de la Villette  
69003 LYON

Tél. 04 72 13 66 67 - Fax 04 72 13 69 50  
RCS Lyon 378 472 872 - TVA n° FR 66 378 472 872

### <sup>1</sup> References:

- Acquadro C., Jambon B., Ellis D. and Marquis P. Language and translation issues. In Spilker B, ed. Quality of Life and Pharmacoeconomics in Clinical Trials. Philadelphia: Lippincott-Raven Publishers, 1996: 575-585.
- Linguistic Validation Manual for Health Outcomes Assessments. Acquadro C, Conway K, Giroulet C, Mear I. Second Edition - Mapi Institute, Lyon, France, January 2012 - ISBN: 2-9522021-0-9